
Keywords: VL; visceral leishmaniasis; PKDL; post-kala-azar dermal leishmaniasis; WHO; World Health Organization; TDR; Tropical Disease Research; HGPRT; hypoxanthine-guanine phosphoribosyltransferase; CDKs; cyclin dependent kinases; Leishmaniasis; Dose regimen; Drug